Daily Archives: August 4, 2017

Alterations in signaling pathways that regulate resolution of inflammation (resolving pathways) contribute to pathogenesis of ulcerative colitis (UC). The resolution process is regulated by lipid mediators, such as those derived from the ω-3 docosahex… Continue reading →

We thank Dr Yu and colleagues for their letter. We agree that the presence of baseline NS5A resistance-associated substitutions in patients with hepatitis C virus genotype 2 infection reduces the efficacy of ultrashort durations of ledipasvir-sofosbuvi… Continue reading →

Question: A 67-year-old man with a history of chronic lymphocytic leukemia (CLL) complicated by recurrent bacterial infections presented to the outpatient clinic with an abrupt onset of altered bowel habits. He reported the urge to defecate several tim… Continue reading →

Thank you, Dr Gin-Ho Lo, for your comments about our randomized controlled trial (RCT) of Doppler endoscopic probe (DEP) as a guide to improving risk stratification and definitive endoscopic hemostasis of severe nonvariceal upper gastrointestinal hemor… Continue reading →

Thank you, Dr Gin-Ho Lo, for your comments about our randomized controlled trial (RCT) of Doppler endoscopic probe (DEP) as a guide to improving risk stratification and definitive endoscopic hemostasis of severe nonvariceal upper gastrointestinal hemor… Continue reading →

Question: A 56-year-old man with a history of mild dysphagia for 4 months experienced worsening of his symptoms when he caught a cold or was tired, but without nausea, vomiting, acid reflux, abdominal pain, or bloating. He had no history of diabetes me… Continue reading →

Question: A 5-year old Caucasian boy presented with sudden onset of diffuse purpuric and petechial skin lesions without fever at the pediatric department. The following days he developed diffuse abdominal pain with bloody stools (4-6 times a day). He a… Continue reading →

We read with great interest the report of Gane et al.1 They evaluated the efficacy and safety of direct-acting antivirals, ledipasvir-sofosbuvir fixed dose combination, for chronic hepatitis C virus genotype 2 infection. The rate of sustained virologi… Continue reading →